Article(id=1329869789054481031, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329869784935674462, articleNumber=null, orderNo=null, doi=10.13683/j.wph.2023.03.014, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1661702400000, receivedDateStr=2022-08-29, revisedDate=null, revisedDateStr=null, acceptedDate=null, acceptedDateStr=null, onlineDate=1794995265495, onlineDateStr=2026-11-18, pubDate=1678377600000, pubDateStr=2023-03-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1794995265495, onlineIssueDateStr=2026-11-18, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1794995265495, creator=13701087609, updateTime=1794995265495, updator=13701087609, issue=Issue{id=1329869784935674462, tenantId=1146029695717560320, journalId=1319690329412173987, year='2023', volume='44', issue='3', pageStart='197', pageEnd='297', issueExtLink='null', onlineDate='null', pubDate='1678377600000', pubDateStr='2023-03-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1794995264514, creator='13701087609', updateTime=1794995823118, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1329872128242987421, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329869784935674462, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1329872128242987422, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329869784935674462, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=281, endPage=286, ext={EN=ArticleExt(id=1329869789234836104, articleId=1329869789054481031, tenantId=1146029695717560320, journalId=1319690329412173987, language=EN, title=Risk factors and predictors of immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer, columnId=1325221194584162830, journalTitle=World Clinical Drug, columnName=Review, runingTitle=null, highlight=null, articleAbstract=

Immune checkpoint inhibitors (ICI) have revolutionized the field of cancer treatment. ICI can enhance the antitumor effect, however, it can also induce excessive activation of the immune response, leading to normal tissue damage and trigger immune-related adverse events. In the immunotherapy of non-small cell lung cancer (NSCLC), ICI-related pneumonia (CIP) is rare but has extremely high mortality, it occurs from 7% to 13%. Moreover, with the increased use of ICI in NSCLC, identifying high-risk factors and underlying mechanisms for CIP are key points in preventing and monitoring adverse events. This article reviewed the research progress in the pathogenesis, risk factors, and predictive factors of CIP, in order to improve clinical understanding of the disease and provide reference for patient safety management.

, authors=Junran ZHANG, Yingying QIAN*, Wei GU*, authorsList=Junran ZHANG, Yingying QIAN, Wei GU, authorCompany=null, correspAuthors=Yingying QIAN, Wei GU, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1329869789465522825, articleId=1329869789054481031, tenantId=1146029695717560320, journalId=1319690329412173987, language=CN, title=免疫检查点抑制剂相关性肺炎在非小细胞肺癌中的风险因素及预测因子, columnId=1325221194743546384, journalTitle=世界临床药物, columnName=综述评论, runingTitle=null, highlight=null, articleAbstract=

免疫检查点抑制剂(immune checkpoint inhibitor,ICI)是恶性肿瘤治疗领域的革命性进展。ICI一方面可以增强机体抗肿瘤免疫力,另一方面也会诱导免疫反应的过度激活,损伤正常组织,引发免疫相关不良事件。在非小细胞肺癌(non-small cell lung cancer,NSCLC)免疫治疗中,ICI相关性肺炎(checkpoint inhibitor-related pneumonitis,CIP)是一种发病率相对较低、死亡率较高的免疫相关不良反应,发生率为7%~13%。随着ICI在NSCLC中的应用增多,识别CIP的高危因素和潜在机制是预防和监测不良反应的关键。该文主要对CIP的发生机制、危险因素及预测因子等相关研究进展作一综述,以期提高临床对该病的认知,为患者的安全管理提供参考。

, authors=张钧然, 钱莹莹*, 谷伟*, authorsList=张钧然, 钱莹莹, 谷伟, authorCompany=null, correspAuthors=钱莹莹, 谷伟, authorNote=

张钧然,硕士研究生,研究方向:肺癌的免疫治疗。

, correspAuthorsNote=
谷伟,主任医师,科主任,硕士生导师,研究方向:肺癌治疗。
钱莹莹,主治医师,研究方向:肺癌的生物靶向治疗及免疫治疗。
, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=spay+VVoEwPS77wMr5Cakg==, magXml=7Zi6Di3dImb4Ot/s4Y33Qw==, pdfUrl=null, pdf=NcSqxWfVTShwJ+pqXjZplw==, pdfFileSize=1568695, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=SyEmmD1DaqxOJ/bgCWMflA==, mapNumber=null, fund=null)}, authors=[Author(id=1329869789750735502, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329869789830427280, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, authorId=1329869789750735502, language=EN, stringName=Junran ZHANG, firstName=Junran, middleName=null, lastName=ZHANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Respiratory, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, Jiangsu Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329869789905924753, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, authorId=1329869789750735502, language=CN, stringName=张钧然, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=南京医科大学附属南京医院(南京市第一医院)呼吸科,江苏 南京 210006, bio={"content":"

张钧然,硕士研究生,研究方向:肺癌的免疫治疗。

"}, bioImg=null, bioContent=

张钧然,硕士研究生,研究方向:肺癌的免疫治疗。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329869789645877898, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, xref=null, ext=[AuthorCompanyExt(id=1329869789654266507, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, companyId=1329869789645877898, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Respiratory, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, Jiangsu Province, China), AuthorCompanyExt(id=1329869789662655116, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, companyId=1329869789645877898, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=南京医科大学附属南京医院(南京市第一医院)呼吸科,江苏 南京 210006)])]), Author(id=1329869789989810835, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1329869790103057045, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, authorId=1329869789989810835, language=EN, stringName=Yingying QIAN, firstName=Yingying, middleName=null, lastName=QIAN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=Department of Respiratory, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, Jiangsu Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329869790186943126, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, authorId=1329869789989810835, language=CN, stringName=钱莹莹, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=南京医科大学附属南京医院(南京市第一医院)呼吸科,江苏 南京 210006, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329869789645877898, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, xref=null, ext=[AuthorCompanyExt(id=1329869789654266507, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, companyId=1329869789645877898, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Respiratory, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, Jiangsu Province, China), AuthorCompanyExt(id=1329869789662655116, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, companyId=1329869789645877898, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=南京医科大学附属南京医院(南京市第一医院)呼吸科,江苏 南京 210006)])]), Author(id=1329869790254051992, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1329869790350520986, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, authorId=1329869790254051992, language=EN, stringName=Wei GU, firstName=Wei, middleName=null, lastName=GU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=Department of Respiratory, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, Jiangsu Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329869790417629851, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, authorId=1329869790254051992, language=CN, stringName=谷伟, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=南京医科大学附属南京医院(南京市第一医院)呼吸科,江苏 南京 210006, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329869789645877898, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, xref=null, ext=[AuthorCompanyExt(id=1329869789654266507, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, companyId=1329869789645877898, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Respiratory, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, Jiangsu Province, China), AuthorCompanyExt(id=1329869789662655116, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, companyId=1329869789645877898, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=南京医科大学附属南京医院(南京市第一医院)呼吸科,江苏 南京 210006)])])], keywords=[Keyword(id=1329869790509904540, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, language=EN, orderNo=1, keyword=immune checkpoint inhibitor), Keyword(id=1329869790564430493, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, language=EN, orderNo=2, keyword=non-small-cell lung cancer), Keyword(id=1329869790614762142, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, language=EN, orderNo=3, keyword=immune checkpoint inhibitor-related pneumonitis), Keyword(id=1329869790677676703, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, language=EN, orderNo=4, keyword=risk factor), Keyword(id=1329869790732202656, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, language=EN, orderNo=5, keyword=predictor), Keyword(id=1329869790799311521, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, language=CN, orderNo=1, keyword=免疫检查点抑制剂), Keyword(id=1329869790858031778, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, language=CN, orderNo=2, keyword=非小细胞肺癌), Keyword(id=1329869790916752035, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, language=CN, orderNo=3, keyword=免疫检查点抑制剂相关性肺炎), Keyword(id=1329869790975472292, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, language=CN, orderNo=4, keyword=风险因素), Keyword(id=1329869791046775461, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, language=CN, orderNo=5, keyword=预测因子)], refs=[Reference(id=1329869791130661542, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=Naidoo J, Wang X, Woo KM, et al. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy[J]. J Clin Oncol, 2017, 35(7): 709-717., articleTitle=null, refAbstract=null), Reference(id=1329869791193576103, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=Yamaguchi T, Shimizu J, Hasegawa T, et al. Pre-existing pulmonary fibrosis is a risk factor for anti-PD-1-related pneumonitis in patients with non-small cell lung cancer: a retrospective analysis[J]. Lung Cancer, 2018, 125: 212-217., articleTitle=null, refAbstract=null), Reference(id=1329869791256490664, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=Suzuki Y, Karayama M, Uto T, et al. Assessment of immune-related interstitial lung disease in patients with NSCLC treated with immune checkpoint inhibitors: a multicenter prospective study[J]. J Thorac Oncol, 2020, 15(8): 1317-1327., articleTitle=null, refAbstract=null), Reference(id=1329869791311016617, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=Atchley WT, Alvarez C, Saxena-Beem S, et al. Immune checkpoint inhibitor-related pneumonitis in lung cancer: real-world incidence, risk factors, and management practices across six health care centers in North Carolina[J]. Chest, 2021, 160(2): 731-742., articleTitle=null, refAbstract=null), Reference(id=1329869791373931178, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer[J]. N Engl J Med, 2015, 373(17): 1627-1639., articleTitle=null, refAbstract=null), Reference(id=1329869791445234347, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=Suresh K, Naidoo J, Zhong Q, et al. The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis[J]. J Clin Invest, 2019, 129(10): 4305-4315., articleTitle=null, refAbstract=null), Reference(id=1329869791520731820, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=Toi Y, Sugawara S, Sugisaka J, et al. Profiling preexisting antibodies in patients treated with anti-PD-1 therapy for advanced non-small cell lung cancer[J]. J Am Med Assoc Oncol, 2019, 5(3): 376-383., articleTitle=null, refAbstract=null), Reference(id=1329869791575257773, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=Tahir SA, Gao J, Miura Y, et al. Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities[J]. Proc Natl Acad Sci U S A, 2019, 116(44): 22246-22251., articleTitle=null, refAbstract=null), Reference(id=1329869791646560942, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=Lin X, Deng H, Yang Y, et al. Peripheral blood biomarkers for early diagnosis, severity, and prognosis of checkpoint inhibitor-related pneumonitis in patients with lung cancer[J]. Front Oncol, 2021, 11: 698832., articleTitle=null, refAbstract=null), Reference(id=1329869791722058415, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=Naqash AR, Yang LV, Sanderlin EJ, et al. Interleukin-6 as one of the potential mediators of immune-related adverse events in non-small cell lung cancer patients treated with immune checkpoint blockade: evidence from a case report[J]. Acta Oncol, 2018, 57(5): 705-708., articleTitle=null, refAbstract=null), Reference(id=1329869791801750192, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=Cui P, Liu Z, Wang G, et al. Risk factors for pneumonitis in patients treated with anti-programmed death-1 therapy: a case-control study[J]. Cancer Med, 2018, 7(8): 4115-4120., articleTitle=null, refAbstract=null), Reference(id=1329869791860470449, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=Moda M, Saito H, Kato T, et al. Tumor invasion in the central airway is a risk factor for early-onset checkpoint inhibitor pneumonitis in patients with non-small cell lung cancer[J]. Thorac Cancer, 2020, 11(12): 3576-3584., articleTitle=null, refAbstract=null), Reference(id=1329869791923385010, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=Reuss JE, Brigham E, Psoter KJ, et al. Pretreatment lung function and checkpoint inhibitor pneumonitis in NSCLC[J]. JTO Clin Res Rep, 2021, 2(10): 100220., articleTitle=null, refAbstract=null), Reference(id=1329869791977910963, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=Kanai O, Kim YH, Demura Y, et al. Efficacy and safety of nivolumab in non-small cell lung cancer with preexisting interstitial lung disease[J]. Thorac Cancer, 2018, 9(7): 847-855., articleTitle=null, refAbstract=null), Reference(id=1329869792036631220, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=Zhang M, Fan Y, Nie L, et al. Clinical outcomes of immune checkpoint inhibitor therapy in patients with advanced non-small cell lung cancer and preexisting interstitial lung diseases: a systematic review and meta-analysis[J]. Chest, 2022, 161(6): 1675-1686., articleTitle=null, refAbstract=null), Reference(id=1329869792107934389, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=Khunger M, Rakshit S, Pasupuleti V, et al. Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: a systematic review and meta-analysis of trials[J]. Chest, 2017, 152(2): 271-281., articleTitle=null, refAbstract=null), Reference(id=1329869792183431862, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=Tanegashima T, Togashi Y, Azuma K, et al. Immune suppression by PD-L2 against spontaneous and treatment-related antitumor immunity[J]. Clin Cancer Res, 2019, 25(15): 4808-4819., articleTitle=null, refAbstract=null), Reference(id=1329869792292483768, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma[J]. N Engl J Med., 2015, 372(26): 2521-2532., articleTitle=null, refAbstract=null), Reference(id=1329869792384758457, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=Su Q, Zhu EC, Wu JB, et al. Risk of pneumonitis and pneumonia associated with immune checkpoint inhibitors for solid tumors: a systematic review and meta-analysis[J]. Front Immunol, 2019, 10: 108., articleTitle=null, refAbstract=null), Reference(id=1329869792451867322, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=Rizvi NA, Cho BC, Reinmuth N, et al. Durvalumab With or without tremelimumab vs standard chemotherapy in first-line treatment of metastatic non-small cell lung cancer: the MYSTIC phase 3 randomized clinical trial[J]. J Am Med Assoc Oncol, 2020, 6(5): 661-674., articleTitle=null, refAbstract=null), Reference(id=1329869792539947707, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer[J]. N Engl J Med, 2018, 378(22): 2078-2092., articleTitle=null, refAbstract=null), Reference(id=1329869792602862269, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=Ahn MJ, Cho BC, Ou X, et al. Osimertinib plus durvalumab in patients with EGFR-mutated, advanced NSCLC: a phase 1b, open-label, multicenter trial[J]. J Thorac Oncol, 2022, 17(5): 718-723., articleTitle=null, refAbstract=null), Reference(id=1329869792665776830, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=Oshima Y, Tanimoto T, Yuji K, et al. EGFR-TKI-associated interstitial pneumonitis in nivolumab-treated patients with non-small cell lung cancer[J]. J Am Med Assoc Oncol, 2018, 4(8): 1112-1115., articleTitle=null, refAbstract=null), Reference(id=1329869792724497087, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=Long YX, Sun Y, Liu RZ, et al. Immune-related pneumonitis was decreased by addition of chemotherapy with PD-1/L1 inhibitors: systematic review and network meta-analysis of randomized controlled trials (RCTs)[J]. Curr Oncol, 2022, 29(1): 267-282., articleTitle=null, refAbstract=null), Reference(id=1329869792787411648, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=Chen X, Zhang Z, Hou X, et al. Immune-related pneumonitis associated with immune checkpoint inhibitors in lung cancer: a network meta-analysis[J]. J Immunother Cancer, 2020, 8(2): e001170., articleTitle=null, refAbstract=null), Reference(id=1329869792879686337, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=null, journalName=null, refType=null, unstructuredReference=Sul J, Blumenthal GM, Jiang X, et al. FDA approval summary: pembrolizumab for the treatment of patients with metastatic non-small cell lung cancer whose tumors express programmed death-ligand 1[J]. Oncologist, 2016, 21(5): 643-650., articleTitle=null, refAbstract=null), Reference(id=1329869792934212290, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=null, journalName=null, refType=null, unstructuredReference=Tamiya A, Tamiya M, Nakahama K, et al. Correlation of radiation pneumonitis history before nivolumab with onset of interstitial lung disease and progression-free survival of patients with pre-treated advanced non-small cell lung cancer[J]. Anticancer Res, 2017, 37(9): 5199-5205., articleTitle=null, refAbstract=null), Reference(id=1329869793001321155, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[28], rfOrder=27, authorNames=null, journalName=null, refType=null, unstructuredReference=Myers CJ, Lu B. Decreased survival after combining thoracic irradiation and an anti-PD-1 antibody correlated with increased T-cell infiltration into cardiac and lung tissues[J]. Int J Radiat Oncol Biol Phys, 2017, 99(5): 1129-1136., articleTitle=null, refAbstract=null), Reference(id=1329869793072624324, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[29], rfOrder=28, authorNames=null, journalName=null, refType=null, unstructuredReference=Von Reibnitz D, Chaft JE, Wu AJ, et al. Safety of combining thoracic radiation therapy with concurrent versus sequential immune checkpoint inhibition[J]. Adv Radiat Oncol, 2018, 3(3): 391-398., articleTitle=null, refAbstract=null), Reference(id=1329869793156510405, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[30], rfOrder=29, authorNames=null, journalName=null, refType=null, unstructuredReference=Cousin F, Desir C, Mustapha SB, et al. Incidence, risk factors, and CT characteristics of radiation recall pneumonitis induced by immune checkpoint inhibitor in lung cancer[J]. Radiother Oncol, 2021, 157: 47-55., articleTitle=null, refAbstract=null), Reference(id=1329869793223619270, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[31], rfOrder=30, authorNames=null, journalName=null, refType=null, unstructuredReference=Suresh K, Voong KR, Shankar B, et al. Pneumonitis in non-small cell lung cancer patients receiving immune checkpoint immunotherapy: incidence and risk factors[J]. J Thorac Oncol, 2018, 13(12): 1930-1939., articleTitle=null, refAbstract=null), Reference(id=1329869793282339527, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[32], rfOrder=31, authorNames=null, journalName=null, refType=null, unstructuredReference=Haanen J, Ernstoff MS, Wang Y, et al. Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy[J]. Ann Oncol, 2020, 31(6): 724-744., articleTitle=null, refAbstract=null), Reference(id=1329869793362031304, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[33], rfOrder=32, authorNames=null, journalName=null, refType=null, unstructuredReference=Asada M, Mikami T, Niimura T, et al. The risk factors associated with immune checkpoint inhibitor-related pneumonitis[J]. Oncology, 2021, 99(4): 256-259., articleTitle=null, refAbstract=null), Reference(id=1329869793429140169, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[34], rfOrder=33, authorNames=null, journalName=null, refType=null, unstructuredReference=Diehl A, Yarchoan M, Hopkins A, et al. Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors[J]. Oncotarget, 2017, 8(69): 114268-114280., articleTitle=null, refAbstract=null), Reference(id=1329869793487860426, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[35], rfOrder=34, authorNames=null, journalName=null, refType=null, unstructuredReference=Chu X, Zhao J, Zhou J, et al. Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors[J]. Lung Cancer, 2020, 150: 76-82., articleTitle=null, refAbstract=null), Reference(id=1329869793554969291, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[36], rfOrder=35, authorNames=null, journalName=null, refType=null, unstructuredReference=Lim SY, Lee JH, Gide TN, et al. Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1-based immunotherapy[J]. Clin Cancer Res, 2019, 25(5): 1557-1563., articleTitle=null, refAbstract=null), Reference(id=1329869793634661068, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[37], rfOrder=36, authorNames=null, journalName=null, refType=null, unstructuredReference=Hoefsmit EP, Rozeman EA, Haanen J, et al. Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse events[J]. ESMO Open, 2019, 4(4): e000472., articleTitle=null, refAbstract=null), Reference(id=1329869793714352845, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[38], rfOrder=37, authorNames=null, journalName=null, refType=null, unstructuredReference=Marschner D, Falk M, Javorniczky NR, et al. MicroRNA-146a regulates immune-related adverse events caused by immune checkpoint inhibitors[J]. JCI Insight, 2020, 5(6): e132334., articleTitle=null, refAbstract=null), Reference(id=1329869793777267406, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[39], rfOrder=38, authorNames=null, journalName=null, refType=null, unstructuredReference=Jin Y, Dong H, Xia L, et al. The diversity of gut microbiome is associated with favorable responses to anti-programmed death 1 immunotherapy in Chinese patients with NSCLC[J]. J Thorac Oncol, 2019, 14(8): 1378-1389., articleTitle=null, refAbstract=null), Reference(id=1329869793840181967, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[40], rfOrder=39, authorNames=null, journalName=null, refType=null, unstructuredReference=Yoshino K, Nakayama T, Ito A, et al. Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: potential role of Th1-dominant immune response in immune-related adverse events: two case reports[J]. Bio Med Central Cancer, 2019, 19(1): 1019., articleTitle=null, refAbstract=null)], funds=null, companyList=[AuthorCompany(id=1329869789645877898, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, xref=null, ext=[AuthorCompanyExt(id=1329869789654266507, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, companyId=1329869789645877898, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Respiratory, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, Jiangsu Province, China), AuthorCompanyExt(id=1329869789662655116, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, companyId=1329869789645877898, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=南京医科大学附属南京医院(南京市第一医院)呼吸科,江苏 南京 210006)])], figs=null, attaches=null, journal=Journal(id=1319689997550452896, delFlag=0, nameCn=世界临床药物, nameEn=World Clinical Drug, nameHistory1=null, nameHistory2=null, issn=1672-9188, eissn=null, cn=31-1939/R, coden=SLYHAA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=9c6IkcJKa1cF20h1u6lJeQ==, journalPrice=null, startedYear=null, abbrevIsoEn=World Clinical Drug, journalRemark=null, publicationField=null, createdTime=1792568214072, updatedTime=1792747519563, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=S, firstLetterEn=S, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=9c6IkcJKa1cF20h1u6lJeQ==, picEn=MRqUlTwfL6oqIHNy7eyFZQ==, jcr=null, cjcr=null, exts=[JournalExt(id=1320442059660570919, language=CN, name=世界临床药物, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519650, updatedTime=1792747519650, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1320442059723485480, language=EN, name=World Clinical Drug, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519665, updatedTime=1792747519665, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1319690329412173987, websiteList=[Website(id=1321427104911179915, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/CN, language=CN, createTime=1792982372739, createBy=18614031015, updateTime=1792982514949, updateBy=18614031015, name=世界临床药物-中文, tplId=1146099689490845704, title=世界临床药物, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428428256031726, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=articleTextType, value=kx, createTime=1792982688249, updateTime=1792982688249, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428193117163, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982688234, updateTime=1792982688234, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428302169073, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=grayFlag, value=0, createTime=1792982688260, updateTime=1792982688260, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428172145642, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982688229, updateTime=1792982688229, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428327334899, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=minRunFlag, value=0, createTime=1792982688266, updateTime=1792982688266, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428226671597, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic, createTime=1792982688242, updateTime=1792982688242, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428314751986, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=silenceFlag, value=0, createTime=1792982688263, updateTime=1792982688263, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428209894380, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982688238, updateTime=1792982688238, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428268614639, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeColor, value=null, createTime=1792982688252, updateTime=1792982688252, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428289586160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982688257, updateTime=1792982688257, creator=18614031015, updator=18614031015)]), Website(id=1321427104990871693, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/EN, language=EN, createTime=1792982372758, createBy=18614031015, updateTime=1792982556355, updateBy=18614031015, name=世界临床药物-英文, tplId=1146101810881728533, title=World Clinical Drug, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428446820021244, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=articleTextType, value=kx, createTime=1792982692675, updateTime=1792982692675, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446757106681, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982692660, updateTime=1792982692660, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447109428223, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=grayFlag, value=0, createTime=1792982692744, updateTime=1792982692744, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446736135160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982692655, updateTime=1792982692655, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447142981632, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=minRunFlag, value=0, createTime=1792982692752, updateTime=1792982692752, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446790661115, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic, createTime=1792982692668, updateTime=1792982692668, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447130399745, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=silenceFlag, value=0, createTime=1792982692749, updateTime=1792982692749, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446769689594, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982692663, updateTime=1792982692663, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446832604157, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeColor, value=null, createTime=1792982692678, updateTime=1792982692678, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447092651006, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982692740, updateTime=1792982692740, creator=18614031015, updator=18614031015)])], journalTitle=世界临床药物, weixinUrl=null, journalUrl=http://www.jwph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=World Clinical Drug, journalPhotoCn=9c6IkcJKa1cF20h1u6lJeQ==, journalPhotoEn=MRqUlTwfL6oqIHNy7eyFZQ==, journalFirstLetter=S, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2023.03.014, detailUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2023.03.014, pdfUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/PDF/10.13683/j.wph.2023.03.014, pdfUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/PDF/10.13683/j.wph.2023.03.014, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1678377600000, fullTextJson=null, articleText=null, reference=null)
收藏切换
免疫检查点抑制剂相关性肺炎在非小细胞肺癌中的风险因素及预测因子
张钧然 , 钱莹莹 * , 谷伟 *
世界临床药物 | 综述评论 2023,44(3): 281-286
收起
收藏切换
世界临床药物 |综述评论 2023 , 44 (3) : 281 -286
免疫检查点抑制剂相关性肺炎在非小细胞肺癌中的风险因素及预测因子
全屏
[Author(id=1329869789750735502, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329869789830427280, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, authorId=1329869789750735502, language=EN, stringName=Junran ZHANG, firstName=Junran, middleName=null, lastName=ZHANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Respiratory, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, Jiangsu Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329869789905924753, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, authorId=1329869789750735502, language=CN, stringName=张钧然, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=南京医科大学附属南京医院(南京市第一医院)呼吸科,江苏 南京 210006, bio={"content":"

张钧然,硕士研究生,研究方向:肺癌的免疫治疗。

"}, bioImg=null, bioContent=

张钧然,硕士研究生,研究方向:肺癌的免疫治疗。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329869789645877898, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, xref=null, ext=[AuthorCompanyExt(id=1329869789654266507, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, companyId=1329869789645877898, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Respiratory, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, Jiangsu Province, China), AuthorCompanyExt(id=1329869789662655116, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, companyId=1329869789645877898, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=南京医科大学附属南京医院(南京市第一医院)呼吸科,江苏 南京 210006)])]), Author(id=1329869789989810835, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1329869790103057045, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, authorId=1329869789989810835, language=EN, stringName=Yingying QIAN, firstName=Yingying, middleName=null, lastName=QIAN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=Department of Respiratory, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, Jiangsu Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329869790186943126, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, authorId=1329869789989810835, language=CN, stringName=钱莹莹, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=南京医科大学附属南京医院(南京市第一医院)呼吸科,江苏 南京 210006, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329869789645877898, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, xref=null, ext=[AuthorCompanyExt(id=1329869789654266507, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, companyId=1329869789645877898, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Respiratory, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, Jiangsu Province, China), AuthorCompanyExt(id=1329869789662655116, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, companyId=1329869789645877898, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=南京医科大学附属南京医院(南京市第一医院)呼吸科,江苏 南京 210006)])]), Author(id=1329869790254051992, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1329869790350520986, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, authorId=1329869790254051992, language=EN, stringName=Wei GU, firstName=Wei, middleName=null, lastName=GU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=Department of Respiratory, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, Jiangsu Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329869790417629851, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, authorId=1329869790254051992, language=CN, stringName=谷伟, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=南京医科大学附属南京医院(南京市第一医院)呼吸科,江苏 南京 210006, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329869789645877898, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, xref=null, ext=[AuthorCompanyExt(id=1329869789654266507, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, companyId=1329869789645877898, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Respiratory, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, Jiangsu Province, China), AuthorCompanyExt(id=1329869789662655116, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869789054481031, companyId=1329869789645877898, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=南京医科大学附属南京医院(南京市第一医院)呼吸科,江苏 南京 210006)])])]
张钧然, 钱莹莹*, 谷伟*
作者信息
  • 南京医科大学附属南京医院(南京市第一医院)呼吸科,江苏 南京 210006
通讯作者:
谷伟,主任医师,科主任,硕士生导师,研究方向:肺癌治疗。
钱莹莹,主治医师,研究方向:肺癌的生物靶向治疗及免疫治疗。
作者简介:

张钧然,硕士研究生,研究方向:肺癌的免疫治疗。

Risk factors and predictors of immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer
Junran ZHANG, Yingying QIAN*, Wei GU*
Affiliations
  • Department of Respiratory, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, Jiangsu Province, China
出版时间: 2023-03-10 doi: 10.13683/j.wph.2023.03.014
文章导航
收藏切换

免疫检查点抑制剂(immune checkpoint inhibitor,ICI)是恶性肿瘤治疗领域的革命性进展。ICI一方面可以增强机体抗肿瘤免疫力,另一方面也会诱导免疫反应的过度激活,损伤正常组织,引发免疫相关不良事件。在非小细胞肺癌(non-small cell lung cancer,NSCLC)免疫治疗中,ICI相关性肺炎(checkpoint inhibitor-related pneumonitis,CIP)是一种发病率相对较低、死亡率较高的免疫相关不良反应,发生率为7%~13%。随着ICI在NSCLC中的应用增多,识别CIP的高危因素和潜在机制是预防和监测不良反应的关键。该文主要对CIP的发生机制、危险因素及预测因子等相关研究进展作一综述,以期提高临床对该病的认知,为患者的安全管理提供参考。

免疫检查点抑制剂  /  非小细胞肺癌  /  免疫检查点抑制剂相关性肺炎  /  风险因素  /  预测因子

Immune checkpoint inhibitors (ICI) have revolutionized the field of cancer treatment. ICI can enhance the antitumor effect, however, it can also induce excessive activation of the immune response, leading to normal tissue damage and trigger immune-related adverse events. In the immunotherapy of non-small cell lung cancer (NSCLC), ICI-related pneumonia (CIP) is rare but has extremely high mortality, it occurs from 7% to 13%. Moreover, with the increased use of ICI in NSCLC, identifying high-risk factors and underlying mechanisms for CIP are key points in preventing and monitoring adverse events. This article reviewed the research progress in the pathogenesis, risk factors, and predictive factors of CIP, in order to improve clinical understanding of the disease and provide reference for patient safety management.

immune checkpoint inhibitor  /  non-small-cell lung cancer  /  immune checkpoint inhibitor-related pneumonitis  /  risk factor  /  predictor
张钧然, 钱莹莹, 谷伟. 免疫检查点抑制剂相关性肺炎在非小细胞肺癌中的风险因素及预测因子. 世界临床药物, 2023 , 44 (3) : 281 -286 . DOI: 10.13683/j.wph.2023.03.014
Junran ZHANG, Yingying QIAN, Wei GU. Risk factors and predictors of immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer[J]. World Clinical Drug, 2023 , 44 (3) : 281 -286 . DOI: 10.13683/j.wph.2023.03.014

参考文献 引证文献
排序方式:
[1]
Naidoo J, Wang X, Woo KM, et al. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy[J]. J Clin Oncol, 2017, 35(7): 709-717.
[2]
Yamaguchi T, Shimizu J, Hasegawa T, et al. Pre-existing pulmonary fibrosis is a risk factor for anti-PD-1-related pneumonitis in patients with non-small cell lung cancer: a retrospective analysis[J]. Lung Cancer, 2018, 125: 212-217.
[3]
Suzuki Y, Karayama M, Uto T, et al. Assessment of immune-related interstitial lung disease in patients with NSCLC treated with immune checkpoint inhibitors: a multicenter prospective study[J]. J Thorac Oncol, 2020, 15(8): 1317-1327.
[4]
Atchley WT, Alvarez C, Saxena-Beem S, et al. Immune checkpoint inhibitor-related pneumonitis in lung cancer: real-world incidence, risk factors, and management practices across six health care centers in North Carolina[J]. Chest, 2021, 160(2): 731-742.
[5]
Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer[J]. N Engl J Med, 2015, 373(17): 1627-1639.
[6]
Suresh K, Naidoo J, Zhong Q, et al. The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis[J]. J Clin Invest, 2019, 129(10): 4305-4315.
[7]
Toi Y, Sugawara S, Sugisaka J, et al. Profiling preexisting antibodies in patients treated with anti-PD-1 therapy for advanced non-small cell lung cancer[J]. J Am Med Assoc Oncol, 2019, 5(3): 376-383.
[8]
Tahir SA, Gao J, Miura Y, et al. Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities[J]. Proc Natl Acad Sci U S A, 2019, 116(44): 22246-22251.
[9]
Lin X, Deng H, Yang Y, et al. Peripheral blood biomarkers for early diagnosis, severity, and prognosis of checkpoint inhibitor-related pneumonitis in patients with lung cancer[J]. Front Oncol, 2021, 11: 698832.
[10]
Naqash AR, Yang LV, Sanderlin EJ, et al. Interleukin-6 as one of the potential mediators of immune-related adverse events in non-small cell lung cancer patients treated with immune checkpoint blockade: evidence from a case report[J]. Acta Oncol, 2018, 57(5): 705-708.
[11]
Cui P, Liu Z, Wang G, et al. Risk factors for pneumonitis in patients treated with anti-programmed death-1 therapy: a case-control study[J]. Cancer Med, 2018, 7(8): 4115-4120.
[12]
Moda M, Saito H, Kato T, et al. Tumor invasion in the central airway is a risk factor for early-onset checkpoint inhibitor pneumonitis in patients with non-small cell lung cancer[J]. Thorac Cancer, 2020, 11(12): 3576-3584.
[13]
Reuss JE, Brigham E, Psoter KJ, et al. Pretreatment lung function and checkpoint inhibitor pneumonitis in NSCLC[J]. JTO Clin Res Rep, 2021, 2(10): 100220.
[14]
Kanai O, Kim YH, Demura Y, et al. Efficacy and safety of nivolumab in non-small cell lung cancer with preexisting interstitial lung disease[J]. Thorac Cancer, 2018, 9(7): 847-855.
[15]
Zhang M, Fan Y, Nie L, et al. Clinical outcomes of immune checkpoint inhibitor therapy in patients with advanced non-small cell lung cancer and preexisting interstitial lung diseases: a systematic review and meta-analysis[J]. Chest, 2022, 161(6): 1675-1686.
[16]
Khunger M, Rakshit S, Pasupuleti V, et al. Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: a systematic review and meta-analysis of trials[J]. Chest, 2017, 152(2): 271-281.
[17]
Tanegashima T, Togashi Y, Azuma K, et al. Immune suppression by PD-L2 against spontaneous and treatment-related antitumor immunity[J]. Clin Cancer Res, 2019, 25(15): 4808-4819.
[18]
Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma[J]. N Engl J Med., 2015, 372(26): 2521-2532.
[19]
Su Q, Zhu EC, Wu JB, et al. Risk of pneumonitis and pneumonia associated with immune checkpoint inhibitors for solid tumors: a systematic review and meta-analysis[J]. Front Immunol, 2019, 10: 108.
[20]
Rizvi NA, Cho BC, Reinmuth N, et al. Durvalumab With or without tremelimumab vs standard chemotherapy in first-line treatment of metastatic non-small cell lung cancer: the MYSTIC phase 3 randomized clinical trial[J]. J Am Med Assoc Oncol, 2020, 6(5): 661-674.
[21]
Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer[J]. N Engl J Med, 2018, 378(22): 2078-2092.
[22]
Ahn MJ, Cho BC, Ou X, et al. Osimertinib plus durvalumab in patients with EGFR-mutated, advanced NSCLC: a phase 1b, open-label, multicenter trial[J]. J Thorac Oncol, 2022, 17(5): 718-723.
[23]
Oshima Y, Tanimoto T, Yuji K, et al. EGFR-TKI-associated interstitial pneumonitis in nivolumab-treated patients with non-small cell lung cancer[J]. J Am Med Assoc Oncol, 2018, 4(8): 1112-1115.
[24]
Long YX, Sun Y, Liu RZ, et al. Immune-related pneumonitis was decreased by addition of chemotherapy with PD-1/L1 inhibitors: systematic review and network meta-analysis of randomized controlled trials (RCTs)[J]. Curr Oncol, 2022, 29(1): 267-282.
[25]
Chen X, Zhang Z, Hou X, et al. Immune-related pneumonitis associated with immune checkpoint inhibitors in lung cancer: a network meta-analysis[J]. J Immunother Cancer, 2020, 8(2): e001170.
[26]
Sul J, Blumenthal GM, Jiang X, et al. FDA approval summary: pembrolizumab for the treatment of patients with metastatic non-small cell lung cancer whose tumors express programmed death-ligand 1[J]. Oncologist, 2016, 21(5): 643-650.
[27]
Tamiya A, Tamiya M, Nakahama K, et al. Correlation of radiation pneumonitis history before nivolumab with onset of interstitial lung disease and progression-free survival of patients with pre-treated advanced non-small cell lung cancer[J]. Anticancer Res, 2017, 37(9): 5199-5205.
[28]
Myers CJ, Lu B. Decreased survival after combining thoracic irradiation and an anti-PD-1 antibody correlated with increased T-cell infiltration into cardiac and lung tissues[J]. Int J Radiat Oncol Biol Phys, 2017, 99(5): 1129-1136.
[29]
Von Reibnitz D, Chaft JE, Wu AJ, et al. Safety of combining thoracic radiation therapy with concurrent versus sequential immune checkpoint inhibition[J]. Adv Radiat Oncol, 2018, 3(3): 391-398.
[30]
Cousin F, Desir C, Mustapha SB, et al. Incidence, risk factors, and CT characteristics of radiation recall pneumonitis induced by immune checkpoint inhibitor in lung cancer[J]. Radiother Oncol, 2021, 157: 47-55.
[31]
Suresh K, Voong KR, Shankar B, et al. Pneumonitis in non-small cell lung cancer patients receiving immune checkpoint immunotherapy: incidence and risk factors[J]. J Thorac Oncol, 2018, 13(12): 1930-1939.
[32]
Haanen J, Ernstoff MS, Wang Y, et al. Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy[J]. Ann Oncol, 2020, 31(6): 724-744.
[33]
Asada M, Mikami T, Niimura T, et al. The risk factors associated with immune checkpoint inhibitor-related pneumonitis[J]. Oncology, 2021, 99(4): 256-259.
[34]
Diehl A, Yarchoan M, Hopkins A, et al. Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors[J]. Oncotarget, 2017, 8(69): 114268-114280.
[35]
Chu X, Zhao J, Zhou J, et al. Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors[J]. Lung Cancer, 2020, 150: 76-82.
[36]
Lim SY, Lee JH, Gide TN, et al. Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1-based immunotherapy[J]. Clin Cancer Res, 2019, 25(5): 1557-1563.
[37]
Hoefsmit EP, Rozeman EA, Haanen J, et al. Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse events[J]. ESMO Open, 2019, 4(4): e000472.
[38]
Marschner D, Falk M, Javorniczky NR, et al. MicroRNA-146a regulates immune-related adverse events caused by immune checkpoint inhibitors[J]. JCI Insight, 2020, 5(6): e132334.
[39]
Jin Y, Dong H, Xia L, et al. The diversity of gut microbiome is associated with favorable responses to anti-programmed death 1 immunotherapy in Chinese patients with NSCLC[J]. J Thorac Oncol, 2019, 14(8): 1378-1389.
[40]
Yoshino K, Nakayama T, Ito A, et al. Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: potential role of Th1-dominant immune response in immune-related adverse events: two case reports[J]. Bio Med Central Cancer, 2019, 19(1): 1019.
2023年第44卷第3期
14
3
0
引用本文
BibTeX
文章信息
doi: 10.13683/j.wph.2023.03.014
  • 接收时间:2022-08-29
  • 首发时间:2026-11-18
  • 出版时间:2023-03-10
补充材料
相关文章
文章信息
作者
出版历史
  • 收稿日期:2022-08-29
基金
作者信息
    南京医科大学附属南京医院(南京市第一医院)呼吸科,江苏 南京 210006

通讯作者:

谷伟,主任医师,科主任,硕士生导师,研究方向:肺癌治疗。
钱莹莹,主治医师,研究方向:肺癌的生物靶向治疗及免疫治疗。
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2023.03.014
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏